 |
|
Hope for patients with COPD
August 15, 2008For the first time, a drug therapy appears to reduce lung function loss in patients with moderate to severe chronic obstructive pulmonary disease (COPD), according to the results of a randomized, double-blind, placebo-controlled trial in 42 countries.
The Toward a Revolution in COPD Health (TORCH) study investigated the effects of combined salmeterol, a ß-agonist, and fluticasone propiniate, an inhaled cortical steroid, either alone or in combination, on mortality, exacerbations, health-related quality of life and rate of decline in lung function as measure by forced expiratory volume in one second (FEV1) in patients with COPD.
The results are published in the second issue for August of the American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.
"Pharmacotherapy with salmeterol plus fluticasone propionate, or the components, reduces the rate of decline on FEV1 in patients with moderate to severe COPD, thus slowing disease progression," wrote Bartolome R. Celli, M.D., lead author of the study and professor at Tufts University School of Medicine. "To date, smoking cessation is the only intervention that has conclusively been shown to alter the rate of decline in FEV1," remarked Dr. Celli. This is the first demonstration of an effective pharmacothrerapy in COPD.
The TORCH study randomized more than 6,000 patients with moderate to severe COPD from 42 countries to receive either salmeterol (SAL; 50 g), fluticasone propionate (FP; 500 g), the two in combination (SFC; 50/500g), or placebo. After baseline FEV1 was recorded, patients were re-evaluated every 24 weeks to determine the rate of decline in FEV1.
"The rate of decline in FEV1 was slowest in patients on SFC and fastest in those randomized to the placebo arm," wrote Dr. Celli. "From week 24 onward, the adjusted rate of decline in FEV1 was 39ml/year for SFC, 42 ml/year for both SAL and FP and 55 ml/year for placebo."
Although the study was not formally powered to detect differences in rate of decline of FEV1, the results were highly significant (p<0.001.) The rate of decline in treatment groups was similar across a number of variables, including sex, age, ethnicity and body mass index. Furthermore, the slower rate of decline in FEV1 appeared to be associated with a lower risk of exacerbation.
"Although treatment did not abolish the accelerated decline in lung function [that occurs with COPD], it did ameliorate it substantially," wrote Dr. Celli, while noting that "the mechanism responsible for the effect on rate of decline is not clear, as all treatments have potentially significant nonbronchodilator effects." Clarifying those mechanisms is the goal of the next phase of the research, with the comparison between a long-acting bronchodilator drug and placebo with respect to FEV1 decline.
In the meantime, "the TORCH study brings some clarity to the treatment picture and provides some hopeful signs for patients with COPD," wrote Samy Suissa, Ph.D., of McGill University, in the accompanying editorial. "This study also demonstrates that no treatment [placebo] is not an option for patients with moderate to severe COPD."
American Thoracic Society
"Pharmacotherapy with salmeterol plus fluticasone propionate, or the components, reduces the rate of decline on FEV1 in patients with moderate to severe COPD, thus slowing disease progression," wrote Bartolome R. Celli, M.D., lead author of the study and professor at Tufts University School of Medicine. "To date, smoking cessation is the only intervention that has conclusively been shown to alter the rate of decline in FEV1," remarked Dr. Celli. This is the first demonstration of an effective pharmacothrerapy in COPD.
The TORCH study randomized more than 6,000 patients with moderate to severe COPD from 42 countries to receive either salmeterol (SAL; 50 g), fluticasone propionate (FP; 500 g), the two in combination (SFC; 50/500g), or placebo. After baseline FEV1 was recorded, patients were re-evaluated every 24 weeks to determine the rate of decline in FEV1.
"The rate of decline in FEV1 was slowest in patients on SFC and fastest in those randomized to the placebo arm," wrote Dr. Celli. "From week 24 onward, the adjusted rate of decline in FEV1 was 39ml/year for SFC, 42 ml/year for both SAL and FP and 55 ml/year for placebo."
Although the study was not formally powered to detect differences in rate of decline of FEV1, the results were highly significant (p<0.001.) The rate of decline in treatment groups was similar across a number of variables, including sex, age, ethnicity and body mass index. Furthermore, the slower rate of decline in FEV1 appeared to be associated with a lower risk of exacerbation.
"Although treatment did not abolish the accelerated decline in lung function [that occurs with COPD], it did ameliorate it substantially," wrote Dr. Celli, while noting that "the mechanism responsible for the effect on rate of decline is not clear, as all treatments have potentially significant nonbronchodilator effects." Clarifying those mechanisms is the goal of the next phase of the research, with the comparison between a long-acting bronchodilator drug and placebo with respect to FEV1 decline.
In the meantime, "the TORCH study brings some clarity to the treatment picture and provides some hopeful signs for patients with COPD," wrote Samy Suissa, Ph.D., of McGill University, in the accompanying editorial. "This study also demonstrates that no treatment [placebo] is not an option for patients with moderate to severe COPD."
American Thoracic Society
Chronic Obstructive Pulmonary Disease Current Events and Chronic Obstructive Pulmonary Disease News RSSSurvey: Awareness of COPD is rising, but understanding is still low
Awareness of COPD-chronic obstructive pulmonary disease-continues to grow in the United States, according to national survey results released today by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health.
'Superobesity,' chronic disease burden associated with risk of death following bariatric surgery
Veterans classified as superobese and those with a higher chronic disease burden appear more likely to die within a year of having bariatric surgery, according to a report in the October issue of Archives of Surgery, one of the JAMA/Archives journals.
Portable and precise gas sensor could monitor pollution and detect disease
In the air, it is a serious pollutant. In the body, it plays a role in heart rate, blood flow, nerve signals and immune function.
UT scientists discover link between protein and lung disease
In a development that could lead to a novel approach to the treatment of a devastating lung disease, biochemists at The University of Texas Health Science Center at Houston report they are the first to link the osteopontin (OPN) protein to chronic obstructive pulmonary disease (COPD).
New vaccine shows promise for COPD patients at risk for pneumonia
A new vaccine against pneumonia may offer better protection from chronic obstructive pulmonary disease (COPD) patients than the currently accepted vaccine, according to recent research that will be published in the September 15 issue of the American Journal of the Respiratory and Critical Care Journal, a publication of the American Thoracic Society.
ADA publishes practice guidelines for nutrition care for patients with spinal cord injury
The American Dietetic Association has published new evidence-based nutrition practice guidelines for registered dietitians on nutrition care for patients with spinal cord injury.
LSUHSC shows for first time infant inhalation of ultrafine air pollution linked to adult lung disease
Stephania Cormier, Ph.D., Associate Professor of Pharmacology at LSU Health Sciences Center New Orleans, has shown for the first time that early exposure to environmentally persistent free radicals (present in airborne ultrafine particulate matter) affects long-term lung function.
Severe COPD may lead to cognitive impairment
Severe chronic obstructive pulmonary disease (COPD) is associated with lower cognitive function in older adults, according to research from Mount Sinai School of Medicine.
Group Health Cooperative shows investing in more primary care pays for itself
An evaluation of recent innovations in delivering primary care at a Group Health Cooperative medical center shows significant success and rapid return on investment.
Top notch decisions in the developing airways bring insights into lung disease
In the normal lung, the airways are lined by a balanced mixture of ciliated, secretory and neuroendocrine cells which perform functions as diverse as air humidification, detoxification, and clearance of environmental particles.
More Chronic Obstructive Pulmonary Disease Current Events and Chronic Obstructive Pulmonary Disease News Articles
 |
Chronic Obstructive Pulmonary Disease (Fast Facts) by William Macnee (Author), Stephen I., M.D. Rennard (Author) Chronic obstructive pulmonary disease (COPD) is a heterogeneous collection of respiratory syndromes with overlapping manifestations. As well as the characteristic shortness of breath, the disease is associated with a number of comorbidities that can present major clinical problems for the individual. This fully updated second edition of "Fast Facts: Chronic Obstructive Pulmonary Disease" offers a concise and expert review of: the disease process, its causes and progression; diagnostic techniques, including lung function tests and imaging; differential diagnoses; the main clinical features, systemic effects and comorbidities; current treatments to reduce symptoms and improve lung function in stable disease; the prevention and management of acute exacerbations; the latest clinical trial... |
 |
FlameEz-Lung, 60 Capsules/Bottle by FlameEz Chronic Obstructive Pulmonary Disease (COPD) is progressive inflammatory disease affecting the respiratory tract and the lungs. Inflammation causes destruction of airways and lung tissues. If inflammation persists, the damage to the airways and lungs may not be reversed. Recent studies also suggest that inflammation is a critical component in lung cancer development, progression and metastasis. Inflammation induces the release of a variety of inflammatory cytokines that cause oxidative damage, DNA mutation, and cell transformation. Inflammation also plays a key role in survival and expansion of tumor cells. Since tumor cells produce various substances that attract inflammatory cells, which are indispensable participants in tissue disruption and metastasis, inflammation has been described... |
 |
COPD: The Struggle To Breath (Home Use) Part of the award winning public television series Healthy Body/Healthy Mind. Chronic Obstructive Pulmonary Disease is an umbrella term used to describe patients with Chronic Bronchitis and/or Emphysema. The condition causes shortness of breath and can restrict mobility, making simple tasks like walking to the car seem almost impossible. Learn more about this chronic disease and how to cope with the condition. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
 |
COPD Awareness Ribbon Mouse Pad by MyHeritageWear.com The COPD Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the COPD Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your COPD Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness! |
 |
Chronic Respiratory Disorders (118) CD-ROM by Concept Media, a division of Jobson Medical Information LLC 5 CD series including these programs: [118.1] Chronic Obstructive Pulmonary Disease; [118.2] Cystic Fibrosis; |
 |
Chronic Obstructive Pulmonary Disease (COPD) Anatomical Chart Unmounted by lww Defines COPD along with causes, symptoms, diagnosis and treatments. Shows respiratory anatomy and illustrates two disorders associated with COPD: Emphysema and Chronic Bronchitis. |
 |
Life and Breath: Preventing, Treating and Reversing Chronic Obstructive Pulmonary Disease by Neil Schachter (Author) The fourth leading cause of death in the United States, COPD, or chronic obstructive pulmonary disease, affects an estimated 35 million Americans. Yet only half are aware that they are seriously ill. Life and Breath, by Dr. Neil Schachter, is the first book that alerts people to their risks for COPD and explains the steps they need to take to prevent the development of this debilitating and often fatal lung disease. Life and Breath begins witha quick quiz to rate your risk for COPD. It explains the steps of a complete pulmonary work-up and teaches you about the painless, inexpensive six-second test that can save your life. We all know that diet, exercise, and environmental changes can reduce the risk of heart disease and some types of cancer. Now, for the first time, Life... |
 |
Coping with COPD: Understanding, Treating, and Living with Chronic Obstructive Pulmonary Disease by Elaine Fantle Shimberg (Author), Thomas L. Petty M.D. (Foreword) The first hands-on guide to living and coping with an insidious disease that affects tens of millions of people Experts estimate that as many as thirty-five million Americans literally cannot catch their breath-they are suffering from Chronic Obstructive Pulmonary Disease. The fourth-leading cause of death in America, COPD is a combination of chronic bronchitis and emphysema with airflow obstruction. In this clear, concise, and up-to-date guide to dealing with and living well with COPD, readers will learn: - How to navigate activities of daily living, from applying make-up to continuing work - How to quite smoking-at any age - How oxygen therapy may help you - How to tailor diet to meet new nutritional needs - How to foster a useful patient/doctor... |
|
Pathophysiology of Chronic Obstructive Pulmonary Disease [VHS] Starring: Lippincott | |
 |
COPD GUIDELINES Pocketcard: American College of Chest Physicians (2008) by International Guidelines Center The COPD Guidelines Pocketcard provides all that is needed to make accurate clinical decisions at the point of care including: Key points: Exacerbations of COPD (ACCP), Management of Stable COPD (GOLD); Management of COPD & Exacerbations Guideline Algorithm (ACCP); Definition of Exacerbation of COPD based on Cardinal Symptoms; Differential Diagnosis of COPD (GOLD); Therapy at Each Stage of COPD (GOLD); Current Medication Tables with Brand and Generic Names; Detailed drug information - strengths, formulations, comments. |
| © 2009 BrightSurf.com |